ECSP11011030A - Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. - Google Patents

Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.

Info

Publication number
ECSP11011030A
ECSP11011030A EC2011011030A ECSP11011030A ECSP11011030A EC SP11011030 A ECSP11011030 A EC SP11011030A EC 2011011030 A EC2011011030 A EC 2011011030A EC SP11011030 A ECSP11011030 A EC SP11011030A EC SP11011030 A ECSP11011030 A EC SP11011030A
Authority
EC
Ecuador
Prior art keywords
warfarine
thrombosis
therapy
prevention
salt
Prior art date
Application number
EC2011011030A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP11011030A publication Critical patent/ECSP11011030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para prevenir el ictus en un paciente que padece fibrilación auricular, en el que el paciente tiene al menos un factor de riesgo para acontecimientos hemorrágicos mayores, comprendiendo el método administrar al paciente 110 mg b.i.d. de etexilato de dabigatrán, opcionalmente en forma de una sal farmacéuticamente aceptable del mismo.
EC2011011030A 2008-11-11 2011-05-04 Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. ECSP11011030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11340408P 2008-11-11 2008-11-11
US23755209P 2009-08-27 2009-08-27

Publications (1)

Publication Number Publication Date
ECSP11011030A true ECSP11011030A (es) 2011-07-29

Family

ID=41463076

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011030A ECSP11011030A (es) 2008-11-11 2011-05-04 Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.

Country Status (21)

Country Link
US (3) US8962574B2 (es)
EP (1) EP2358368A1 (es)
JP (1) JP2013510072A (es)
KR (1) KR20110086700A (es)
CN (2) CN102209544A (es)
AR (1) AR074313A1 (es)
AU (1) AU2009315729A1 (es)
BR (1) BRPI0921479A2 (es)
CA (1) CA2738883A1 (es)
CL (1) CL2011000798A1 (es)
CO (1) CO6361938A2 (es)
EA (1) EA201100756A1 (es)
EC (1) ECSP11011030A (es)
IL (1) IL211852A0 (es)
MA (1) MA32786B1 (es)
MX (1) MX2011004614A (es)
NZ (1) NZ592616A (es)
PE (1) PE20110431A1 (es)
TN (1) TN2011000228A1 (es)
TW (1) TW201022237A (es)
WO (1) WO2010055021A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592616A (en) 2008-11-11 2013-04-26 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
WO2012122024A2 (en) * 2011-03-04 2012-09-13 Russell Medford Screening method for identifying patients at risk of drug induced liver injury
WO2013092497A1 (en) * 2011-12-22 2013-06-27 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
CN103788063B (zh) * 2012-10-29 2016-01-20 天津药物研究院 四水合达比加群酯晶体及其制备方法和药物用途
IN2013CH05441A (es) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
CN104291789B (zh) * 2014-09-28 2016-03-02 定远县绿苑新型建材有限公司 一种吸水性强的多孔砖及其制备方法
CN105560236B (zh) * 2014-10-30 2019-03-15 成都百裕制药股份有限公司 一种含有银杏内酯b和非肽类凝血酶抑制剂的药物组合物及其制备方法和用途
CN108133754B (zh) * 2017-12-19 2019-03-12 中国医学科学院阜外医院 一种溶栓后出血风险的预测系统
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
CN111983085B (zh) * 2020-08-21 2022-05-31 江苏省食品药品监督检验研究院 一组血清代谢标志物在预测华法林个体药效和指导华法林个体化用药中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4145308A (en) 1977-07-07 1979-03-20 General Electric Company Anti-foam silicone emulsion, and preparation and use thereof
US4191741A (en) 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5277820A (en) 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
WO1999041231A1 (fr) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Derives amidino utilises comme ingredients actifs et medicaments les contenant
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1807086A1 (en) 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US20060222640A1 (en) 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
US20070079972A1 (en) 2005-09-23 2007-04-12 Fireaway Llc Manually activated, portable fire-extinguishing aerosol generator
DE102005061624A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005061623A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
EP2043691A1 (en) 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New paediatric indications for direct thrombin inhibitors
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
WO2008009639A2 (en) 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
JP2010505906A (ja) 2006-10-10 2010-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルの生理学的に許容される塩
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1956018A1 (de) 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
WO2009118322A1 (en) 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Process for preparing orally administered dabigatran formulations
NZ588488A (en) 2008-06-16 2012-08-31 Boehringer Ingelheim Int Method for producing an intermediate product of dabigatran etexilate
WO2009153214A1 (en) 2008-06-16 2009-12-23 Boehringer Ingelheim International Gmbh Process for the manufacture of an intermediate in the synthesis of dabigatran
BRPI0915942A2 (pt) 2008-07-14 2019-04-09 Boehringer Ingelheim International Gmbh método para produção de compostos medicinais contendo dabigatrana
WO2010020600A1 (en) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012500244A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍療法におけるダビガトラン
KR20110044230A (ko) 2008-08-19 2011-04-28 베링거 인겔하임 인터내셔날 게엠베하 경피적 중재 심장 카테터 삽입을 위한 다비가트란
NZ592616A (en) 2008-11-11 2013-04-26 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
BRPI0921353A2 (pt) 2008-11-11 2015-12-29 Boehringer Ingelheim Int método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional.
CN102209546A (zh) 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
ES2525251T3 (es) 2009-02-02 2014-12-19 Boehringer Ingelheim International Gmbh Dabigatrán liofilizado
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate

Also Published As

Publication number Publication date
NZ592616A (en) 2013-04-26
IL211852A0 (en) 2011-06-30
CA2738883A1 (en) 2010-05-20
US20100322869A1 (en) 2010-12-23
US20110269703A1 (en) 2011-11-03
CO6361938A2 (es) 2012-01-20
JP2013510072A (ja) 2013-03-21
KR20110086700A (ko) 2011-07-29
CL2011000798A1 (es) 2012-01-27
PE20110431A1 (es) 2011-07-13
MA32786B1 (fr) 2011-11-01
BRPI0921479A2 (pt) 2016-01-12
TW201022237A (en) 2010-06-16
CN102209544A (zh) 2011-10-05
CN103356614A (zh) 2013-10-23
US8962574B2 (en) 2015-02-24
MX2011004614A (es) 2011-05-31
AU2009315729A1 (en) 2010-05-20
US20120282187A1 (en) 2012-11-08
TN2011000228A1 (en) 2012-12-17
EP2358368A1 (en) 2011-08-24
WO2010055021A1 (en) 2010-05-20
AR074313A1 (es) 2011-01-05
EA201100756A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
UY35962A (es) Formulaciones de liberación modificada de pridopidina
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
BR112015020466A2 (pt) inibidores de cdc7
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
AR119158A1 (es) Tratamientos de angioedema hereditario
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
AR119159A1 (es) Tratamientos de angioedema
EA201490199A1 (ru) Терапевтические способы
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AR072954A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal